Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SBP 101 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Sun BioPharma
  • Most Recent Events

    • 13 Nov 2019 According to a Sun BioPharma media release, the company has has opened new clinical sites at the University of Rochester in Rochester, New York and Scripps MD Anderson Cancer Center in San Diego, California and Several additional sites are planned to be open in the first half of 2020.
    • 13 Nov 2019 According to a Sun BioPharma media release, enrollment in the third dose level cohort has been completed in October and the company plans to add a fourth cohort to the study protocol to examine an alternative and more convenient dosing schedule Following an upcoming meeting of the Data Safety Monitoring Board (DSMB).
    • 17 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top